Independent Monitoring Committee

Positive Results for Xtandi in the Pre-Chemotherapy Space

It was announced today that after observing significant benefits in overall survival (OS) and radiographic progression free survival (PFS) ,the two co-primary endpoints of the the Xtandi pre-chemotherapy trial, the Independent Data Monitoring Committee (IDMC) for The Phase 3 PREVAIL trial of enzalutamide in metastatic prostate cancer recommends that "the study be stopped and patients [...]

By Malecare|2017-10-19T10:49:22-04:00October 22nd, 2013|Advanced Prostate Cancer, Drugs & Treatments, Early/Expanded Access Programs, enzalutamide, Enzalutamide (MDV-3100), Fail First Therapy, General Information, Provenge, step therapy, Uncategorized, Understanding APC, Xtandi, Zytiga|1 Comment

Takeda Un-blinds & Halts the Phase 3 Study of Orteronel in Men with mCRPC That Progressed Post-Chemotherapy

A press release made yesterday brought some bad news to the advanced prostate cancer community. Takeda Pharmaceutical Company Limited (“Takeda”) announced that it has un-blinded and stopped the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed [...]

By Malecare|2017-10-19T10:49:37-04:00July 26th, 2013|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, TAK700|0 Comments